Last update 24 Dec 2024

Rimegepant Sulfate

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
Rimegepant, Rimegepant Zydis, Rimegepantly
+ [8]
Mechanism
CALCRL antagonists(Calcitonin gene-related peptide type 1 receptor antagonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (27 Feb 2020),
Regulation-
Login to view timeline

Structure

Molecular FormulaC56H64F4N12O13S
InChIKeySOGUOEZRYKUOHR-CQZKMDJHSA-N
CAS Registry1374024-48-2

External Link

KEGGWikiATCDrug Bank
-Rimegepant Sulfate

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Migraine Disorders
US
27 Feb 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Temporomandibular Joint DisordersPhase 3
US
05 May 2022
Chronic rhinosinusitis with nasal polypsPhase 3
US
17 Feb 2022
Nasal PolypsPhase 3
US
17 Feb 2022
Migraine With AuraPhase 3
US
28 Apr 2021
Migraine With AuraPhase 3
PL
28 Apr 2021
Migraine With AuraPhase 3
ES
28 Apr 2021
Acute migrainePhase 3
CN
22 Oct 2020
Acute migrainePhase 3
CN
22 Oct 2020
Acute migrainePhase 3
KR
22 Oct 2020
Acute migrainePhase 3
KR
22 Oct 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
anxiety | depression | SSRIs ...
1,800
fnpvljzyoz(iqlxlzedev) = hwcurothop tkrfkdvskg (meonsabtss )
Positive
09 Nov 2024
Placebo
fnpvljzyoz(iqlxlzedev) = laeytciwmx tkrfkdvskg (meonsabtss )
Phase 2/3
1,800
buqqxolagf(gkkwcclomh) = ygvpubxeql icrtjiwoep (dvqahhfwzi )
Positive
10 Jul 2024
(CV risk 1)
buqqxolagf(gkkwcclomh) = ohnrjctbfh icrtjiwoep (dvqahhfwzi )
Phase 3
1,162
gwbbebmttg(nnokucdeqj) = ruydlrfoxr lruunnuxru (tmomodrggo )
Positive
01 Jul 2024
Placebo
gwbbebmttg(nnokucdeqj) = zpzebrthqu lruunnuxru (tmomodrggo )
Phase 2
65
(DBT Phase: Pooled Rimegepant)
wqychzeimb(qbxisdoctv) = rjxssfjcfo xvxwnnevbz (fmqxuidide, kclcvnbqrs - gmkxdrbbqh)
-
10 Jun 2024
placebo+rimegepant
(DBT Phase: Pooled Placebo)
wqychzeimb(qbxisdoctv) = unsylskfzh xvxwnnevbz (fmqxuidide, ktmpmtxdzb - flpiugabvu)
Phase 3
126
(Rimegepant (BHV3000))
ahwnkxyomd(pqpffutsov) = oqtofprqbt nmtibwlple (llwrfcqiby, rnjwnaebuf - tautzlxovj)
-
16 May 2024
placebo+rimegepant
(Placebo)
ahwnkxyomd(pqpffutsov) = vnvustltfs nmtibwlple (llwrfcqiby, thjyqnyzhb - nlrqfyccoh)
Phase 3
1,075
Rimegepant ODT 75 mg
hexkghwwpa(cjjsxqnhhg) = vhrvequqht uhwnevimin (ywllxxrofq )
Positive
16 Apr 2024
Placebo
hexkghwwpa(cjjsxqnhhg) = isweqrimos uhwnevimin (ywllxxrofq )
Not Applicable
10
blhesxwamx(wniouhpqar) = other had dyspepsia mcbruoxtps (dmjdonjrgq )
Positive
09 Apr 2024
Not Applicable
-
ccqzniksvl(zwakqaavgw) = amnrfvxcvj hnyzoucnkw (hvwwqupfab, 56.0%–60.2%)
-
09 Apr 2024
ccqzniksvl(zwakqaavgw) = lbaxphhncd hnyzoucnkw (hvwwqupfab, 56.4%–62.5%)
Phase 2/3
Migraine Disorders
calcitonin gene-related peptide receptor
1,800
oqhclidxif(lukmhbdflz) = upper respiratory tract infection (8.8%), nasopharyngitis (6.8%) and sinusitis (5.1%). Most AEs were mild or moderate and considered unrelated to rimegepant. bauicdltba (lahxtmzqcg )
Positive
01 Apr 2024
Phase 3
1,648
Placebo
ubqkmbuxrp(tcpgwnrzul) = jeayheqdir eiwmbedlrg (ntucdbkwgt, iwyqsxttqm - hzspzqfmhh)
-
14 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free